Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Longterm survival after curative resection for adenocarcinoma at the gastro-esophageal junction (GEJ) range between 18% and 50%. In the pivotal Intergroup-0116 Phase III trial by Macdonald et all, adjuvant chemoradiotherapy improved both disease-free and overall survival in curatively resected patients with mainly gastric adenocarcinoma. We compared survival data for curatively resected patients with adeno-carcinoma solely at the gastro-esophageal junction (GEJ), treated with surgery alone or surgery and adjuvant chemoradio-therapy.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Scandinavian Journal of Surgery |
Vol/bind | 101 |
Udgave nummer | 1 |
Sider (fra-til) | 26-31 |
Antal sider | 6 |
ISSN | 1457-4969 |
Status | Udgivet - 2012 |
ID: 48421312